Anna Azvolinsky, PhD

As part of our coverage of the annual ASCO conference, we spoke with Dr. Veronika Bachanova on the role of NK cell therapy in hematologic malignancies.

Patients with metastatic Merkel cell carcinoma treated with pembrolizumab (Keytruda, Merck) as a first-line therapy had durable responses in a phase II clinical trial.

A two-step immunotherapy approach consisting of adoptive T-cell therapy and a dendritic cell vaccine has shown activity in a phase I advanced ovarian cancer clinical trial.